Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CD44 | P16070 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 4/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3014349 | 0.86 | ALDH1A1 (0.58) | KDM4ECD44ALDH1A1CYP3A4TSHR | |
| SCHEMBL29617503 | 0.80 | CD44 (0.41) | CD44ALDH1A1CYP3A4TSHRTP53 | |
| SCHEMBL999991 | 0.80 | CD44 (0.41) | CD44ALDH1A1CYP3A4TSHRTP53 | |
| SCHEMBL139002 | 0.80 | ALDH1A1 (0.65) | KDM4EALDH1A1CYP3A4TSHRTP53 | |
| SCHEMBL30462201 | 0.79 | CD44 (0.44) | KDM4ECD44ALDH1A1CYP3A4TSHR | |
| SCHEMBL203098 | 0.79 | CD44 (0.44) | KDM4ECD44ALDH1A1CYP3A4TSHR | |
| SCHEMBL525350 | 0.79 | CYP3A4 (0.65) | CD44ALDH1A1CYP3A4TSHRTP53 | |
| SCHEMBL1392591 | 0.79 | CYP3A4 (0.65) | CD44ALDH1A1CYP3A4TSHRTP53 | |
| SCHEMBL5505433 | 0.79 | CD44 (0.44) | KDM4ECD44ALDH1A1CYP3A4TSHR | |
| Bromide SCHEMBL2026165 | 0.78 | CD44 (0.39) | CD44ALDH1A1CYP3A4TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 323 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-1668082-B1 | LAKED AZO RED PIGMENT AND PROCESSES FOR PREPARATION AND USE | BASF CATALYSTS LLC (US) | 2013-01-09 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| EP-1668082-A1 | LAKED AZO RED PIGMENT AND PROCESSES FOR PREPARATION AND USE | Engelhard Corporation (US) | 2006-06-14 | — | — | EP | claimed |
| US-7041421-B2 | Laked azo red pigment and processes for preparation and use | ENGELHARD CORPORATION (US) | 2006-05-09 | — | — | US | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-6902612-B2 | Heat stable laked monoazo red pigment | ENGELHARD CORPORATION (US) | 2005-06-07 | — | — | US | claimed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| WO-2005026265-A1 | LAKED AZO RED PIGMENT AND PROCESSES FOR PREPARATION AND USE | ENGELHARD CORPORATION (US) | 2005-03-24 | — | — | WO | claimed |
| US-20050054385-A1 | Laked azo red pigment and processes for preparation and use | ENGELHARD CORPORATION | 2005-03-10 | — | — | US | claimed |
| US-20050051050-A1 | Heat stable laked monoazo red pigment | ENGELHARD CORPORATION | 2005-03-10 | — | — | US | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| US-12600844-B2 | Linear low density polyethylene for film applications | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12577334-B2 | Broad orthogonal distribution polyethylenes for films | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-4060635-A | Amidinoureas for treating diarrhea | WILLIAM H. RORER, INC. (US) | 1977-11-29 | — | — | US | disclosed |
| US-3962209-A | PROCESS FOR PREPARING AZO DYESTUFFS WITH ORTHO-AZO CYANO GROUPS BY CYANO EXCHANGE OF METAL CYANIDES AND HALO DYESTUFFS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | KDM4E 2744/4885CD44 4839/4885ALDH1A1 3722/4885 |
| US-12577334-B2 | Broad orthogonal distribution polyethylenes for films | CDR2, LBR, FCER2 | KDM4E 1244/4885CD44 2556/4885ALDH1A1 4599/4885 |
| US-12600844-B2 | Linear low density polyethylene for film applications | RPS2, RPSA, LBR | KDM4E 2286/4885CD44 2253/4885ALDH1A1 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.